the aid library

LIST OPTIONS

Filter

11982

Sort by:

Direction:

Download (149)

View PDF (330)

WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer

World Health Organization WHO (2020) C_WHO

Globally, 311,000 women die of cervical cancer every year, 85 percent of them in resource limited regions of the world. To address this grave threat to women, the WHO made a call to action in 2018, resulting in accelerated plans to improve cervical cancer control under the elimination threshold w... more

Download (211)

View PDF (397)

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

World Health Organization (2019) C_WHO

It is estimated that more than 311 000 women die of cervical cancer each year. Of these deaths, 91% occur in low- and middle-income countries. Demographic changes and a lack of action mean that the number of deaths per year is projected to reach 460 000 by 2040.

Download (211)

View PDF (190)

Obstetric Fistula Strategic Plan 2022 - 2026

Government of Zambia World Health Organisation (WHO) Regional Office Africa (2023) C_WHO

Globally, over two million women live with obstetric fistula with the majority of the cases being from Africa. In low-resource settings such as Zambia, obstetric fistula (OF) is a visible indicator of gaps in maternal health care resulting in failure to provide adequate, accessible and quality m... more

Download (247)

View PDF (332)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (173)

View PDF (149)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (211)

View PDF (187)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (115)

View PDF (114)

WHO Guide to conducting programme reviews for HIV, viral hepatitis and sexually transmitted infections

World Health Organization WHO (2023) C_WHO

Sound periodic programme reviews provide opportunities for countries to objectively assess progress and take corrective action to sustain or get back on track towards achieving their medium and long-term programme goals. It reflects people’s diverse needs, enables efficient use of health system re... more

Download (187)

View PDF (213)

Ending the neglect to attain the sustainable development goals: a rationale for continued investment in tackling neglected tropical diseases 2021–2030

World Health Organization WHO (2022) C_WHO

This document sets out, therefore, to explain the socioeconomic value of investing in the fight against NTDs and highlights priorities for global investment attention. Our work was guided by the need not only for additional funding and funders but also for the need to understand the current funding... more

Download (140)

View PDF (115)

Communicating about Vaccination-related Risks

World Health Organisation (WHO) (2023) C_WHO

This document seeks to help health communication professionals working on the topic of immunization more effectively communicate about Events Supposedly Attributed to Vaccination and Immunization (ESAVI) by building trust in National Immunization Programs, understanding risk perceptions related to v... more

Download (120)

View PDF (124)

Tuberculosis in the WHO African Region: 2023 progress update - September 2023

World Health Organisation (WHO) (2023) C_WHO

This brief update on tuberculosis (TB) in the African region covers the state of TB in the WHO African region, strategic priorities and targets and the impact of COVID-19 on essential services. This is followed by key figures for the region, the role of WHO in country support and, recognizing the im... more

Download (188)

View PDF (190)

Global report on hypertension: the race against a silent killer
recommended

World Health Organisation (WHO) (2023) C_WHO

This report compiles data for the first time on the far-reaching consequences of uncontrolled hypertension, including heart attacks, strokes and premature death, along with substantial economic losses for communities and countries. It also contains information on the global, regional and country-lev... more

Download (116)

View PDF (124)

Ending disease in Africa: vision, strategies and special initiatives, 2023-2030

World Health Organisation (WHO) (2023) C_WHO

While there has been real progress in addressing the burden of disease in the WHO African region, the COVID-19 pandemic has highlighted the link between health, economics and security, as the region saw decades of progress threatened, including positive trends in decreasing inequality. In the Africa... more

Download (123)

View PDF (116)

Global report on children with developmental disabilities

World Health Organisation (WHO) (2023) C_WHO

Developmental disabilities are common. Yet, children with developmental disabilities have been neglected in health systems planning and policy provisions for health and continue to experience stigmatization, institutionalization, barriers to access health care and inequalities in health and educatio... more

Download (152)

View PDF (163)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

Download (162)

View PDF (163)

Global Strategic preparedness, readiness and response plan for Cholera
recommended

World Health Organisation (WHO) (2023) CC

Cholera is a major health risk in many parts of the world, affecting millions of people every year. Since mid-2021, the world has been facing an acute upsurge of the 7th cholera pandemic, which is characterized by the number, size and concurrence of multiple outbreaks, the spread to areas that had b... more

Download (138)

View PDF (216)

Zimbabwe multi-sectoral cholera elimination plan 2018-2028

World Health Organization WHO; Regional Office for Africa; Cholera Secretariat Zimbabwe (2019) C_WHO

Multi-sectoral Cholera Elimination Plan

Download (251)

View PDF (206)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (140)

View PDF (165)

WHO Global water, sanitation and hygiene: Annual report 2022

World Health Organisation (WHO) (2023) C_WHO

This report summarizes the World Health Organization’s (WHO) global work on water, sanitation and hygiene (WASH) during 2022. It describes how the Organization continued to deliver its essential WASH programming as elaborated in its 2018–2025 strategy.

Download (119)

View PDF (137)

Morbidity management and disability prevention in lymphatic filariasis

World Health Organization (WHO) (2013) C_WHO

The content of these guidelines goes beyond the technicalities of medical needs with additional insights into community empowerment, possible access to welfare and economic opportunities and similar issues. If these are adequately explored, the health and quality of life of people affected and their... more

Download (125)

View PDF (208)

Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031

World Health Organization WHO (2022) C_WHO

Draft plan

Global report on hypertension: the race against a silent killer recommended

Global Strategic preparedness, readiness and response plan for Cholera recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

Global report on hypertension: the race against a silent killer
recommended

Global Strategic preparedness, readiness and response plan for Cholera
recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended